This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

An Observational Study of Avastin (Bevacizumab) in Combination With Interferon Alpha-2a as First-Line Treatment in Patients With Advanced and/or Metastatic Renal Cell Carcinoma

This study has been completed.
Information provided by (Responsible Party):
Hoffmann-La Roche Identifier:
First received: May 9, 2011
Last updated: November 2, 2015
Last verified: November 2015
This observational study will evaluate the safety and efficacy of Avastin (bevacizumab) in combination with interferon alpha-2a as first-line treatment in patients with advanced and/or metastatic renal cell carcinoma. Data will be collected from each patient for up to 4 years.

Renal Cell Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: An Open Label, Prospective, Observational, Non-interventional Study of Bevacizumab in Combination With Interferon Alpha-2a for the First-line Treatment of Patients With Advanced and/or Metastatic Renal Cell Carcinoma

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Safety: Incidence of adverse events [ Time Frame: approximately 4 years ]

Secondary Outcome Measures:
  • Progression-free survival: time from first drug administration to documented disease progression or death of any cause [ Time Frame: approximately 4 years ]
  • Overall response rate: complete response or partial response according to RECIST criteria [ Time Frame: approximately 4 years ]
  • Overall survival [ Time Frame: approximately 4 years ]

Enrollment: 5
Study Start Date: August 2010
Study Completion Date: August 2011
Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with advanced and/or metastatic renal cell carcinoma treated with Avastin and interferon alpha-2a

Inclusion Criteria:

  • Adult patients, >/= 18 years of age
  • Advanced and/or metastatic renal cell carcinoma
  • Receiving first-line treatment with Avastin and interferon alpha-2a according to standard of care and current local label
  • At least one measurable and non-measurable lesion according to RECIST criteria
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • Adequate bone marrow, renal and liver function

Exclusion Criteria:

  • Contraindications to Avastin and/or interferon alpha-2a as per local label
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01351571

Aurangabad, India, 35
Delhi, India, 110085
Sponsors and Collaborators
Hoffmann-La Roche
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Responsible Party: Hoffmann-La Roche Identifier: NCT01351571     History of Changes
Other Study ID Numbers: ML25251
Study First Received: May 9, 2011
Last Updated: November 2, 2015

Additional relevant MeSH terms:
Carcinoma, Renal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Immunologic Factors processed this record on August 22, 2017